# name
The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease

# metadata.dc.description[].value
Summary of the work awarded with the first prize of the First edition of the UB Dr. Antoni i Subirana Chair Award for Research in Pharmacology for the best Master's Degree in Research in Pharmacology at the University of Barcelona

# metadata.dc.description.abstract[].value
Alzheimer’s disease is a severe neurodegenerative disorder that affects approximately 5% of the European population, a percentage that increases substantially among the elderly. It is also the leading cause of dementia in older adults, accounting for more than 60% of cases.
Moreover, it affects not only the individual suffering from the disease but also the patient’s environment—family, friends, and acquaintances—resulting in a significant economic burden. For these reasons, Alzheimer’s disease represents a major public health issue, which becomes even more evident considering the ageing of the population.

# metadata.dc.publisher[].value
Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia
 

# metadata.dc.rights[].value
cc by-nc-nd (c) Badia Fernàndez, Pau, 2025

# metadata.dc.source[].value
Premis (Càtedra UB-Dr Antoni Esteve i Subirana de Recerca en Farmacologia)

# metadata.dc.title[].value
The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease